Diagnosis of Men-I Syndrome on 68Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE

CITEDBY Reports

  1. Robert T. Jensen, Jeffrey A. Norton, . Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas, 2017; 46(5): 589.
    Crossref
  2. Punit Sharma, Anirban Mukherjee, Sellam Karunanithi, Niraj Naswa, Rakesh Kumar, Ariachery C. Ammini, Chandrasekhar Bal, . Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes. Clinical Nuclear Medicine, 2015; 40(7): e351.
    Crossref
  3. Tetsuhide Ito, Robert T Jensen, . Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. International Journal of Endocrine Oncology, 2016; 3(1): 53.
    Crossref
  4. Secondo Lastoria, Francesca Marciello, Antongiulio Faggiano, Luigi Aloj, Corradina Caracò, Michela Aurilio, Laura D’Ambrosio, Francesca Di Gennaro, Valeria Ramundo, Luigi Camera, Leonardo De Luca, Rosa Fonti, Vincenzo Napolitano, Annamaria Colao, . Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine, 2016; 52(3): 488.
    Crossref
  5. Masayuki Imamura, Yuji Nakamoto, Suguru Uose, Izumi Komoto, Masaaki Awane, Yoshiro Taki, . Diagnosis of functioning pancreaticoduodenal neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences, 2015; 22(8): 602.
    Crossref